Health Affairs, 22, no. 3 (2003): 7-8 doi: 10.1377/hlthaff.22.3.7 © 2003 by Project HOPE	New Online   Pay Cuts For Medicare Docs   Access To Care Woes   Public Coverage More Efficient   Empowering Consumers

This Article Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Iglehart, J. K. Search for Related Content PubMed PubMed Citation Articles by Iglehart, J. K.

From the Editor

Will Reference Pricing Address The Health Cost Conundrum?

Few would dispute the value of the brand-name prescription drugs that have been developed over the past several decades and have greatly benefited people afflicted with serious diseases. Because these products are so valued but beyond the financial reach of many people, pharmaceutical companies have come under greater scrutiny than perhaps ever before. While this notoriety stems from a variety of issues, none attracts more attention among policymakers than cost: Prescription drugs are among the fastest-growing components of spending in health care systems around the world. According to IMS Health, worldwide drug sales grew 8 percent last year to $430.3 . . . [Full Text of this Article]

John K. Iglehart

Founding Editor

                      What's this?